Arcturus Therapeutics Holdings Inc. (ARCT)
After hours:
| Previous Close | 24.76 |
| Open | 24.91 |
| Bid | 23.86 x 100 |
| Ask | 23.93 x 100 |
| Day's Range | 23.51 - 25.29 |
| 52 Week Range | 17.52 - 45.00 |
| Volume | |
| Avg. Volume | 409,803 |
| Market Cap | 645.768M |
| Beta (5Y Monthly) | 2.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.69 |
| Earnings Date | Nov 12, 2024 - Nov 18, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 69.11 |
ZacksARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty.
Business WireSelf-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
WALTHAM, Mass. & SAN DIEGO, September 30, 2024--Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and self-amplifying messenger RNA (sa-mRNA) pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced the results of a head-to-head study demonstrating that self-amplifying (sa-mRNA) COVID-19 vaccine maintained superior immunogenicity compared to the conventional mRNA vaccine Comirnaty® for up to one year against Wuhan-Hu-1, Omicron BA.4-5 and certain other variants, and at one-sixth the dos
ZacksHere's Why Investors Should Invest in Arcturus Stock Now
Here, we are discussing some reasons why investing in ARCT stock now may turn out to be a prudent move.
